NASDAQ:EYEN
Eyenovia Inc. Stock News
$0.750
-0.0710 (-8.65%)
At Close: May 17, 2024
Eyenovia to Report First Quarter 2023 Results on Thursday, May 11
08:00am, Thursday, 04'th May 2023
Company to host an investor conference call and webcast at 4:30pm EDT Company to host an investor conference call and webcast at 4:30pm EDT
Eyenovia, Inc. (EYEN) Q4 2022 Earnings Call Transcript
08:44pm, Thursday, 30'th Mar 2023
Eyenovia, Inc. (NASDAQ:EYEN ) Q4 2022 Results Conference Call March 30, 2023 4:30 PM ET Company Participants Eric Ribner - IR Michael Rowe - CEO John Gandolfo - CFO Bren Kern - COO Operator Greetings,
Eyenovia to Report Fourth Quarter and Full-Year 2022 Results on Thursday, March 30
08:00am, Thursday, 23'rd Mar 2023
Company to host an investor conference call and webcast at 4:30 pm ET Company to host an investor conference call and webcast at 4:30 pm ET
Eyenovia: Countdown To May 8, 2023
03:36am, Saturday, 25'th Feb 2023
I will update my previous two articles about Eyenovia. NDA accepted with no outside advisory committee formed to review their submission.
Hoping Eyenovia Has The Aye Votes From The FDA In The Near Future (Rating Downgrade)
01:27am, Tuesday, 13'th Dec 2022
I will update the history I've had with Eyenovia. I will share with the reader the interim and pending events since my previous article.
3 Biotechnology stocks under 10 dollars to buy now
11:30am, Saturday, 26'th Nov 2022
Here are three inexpensive biotech stocks with a bright future ahead of them.
Eyenovia to Present at Upcoming BTIG Ophthalmology Day
04:05pm, Wednesday, 23'rd Nov 2022
NEW YORK, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its
Eyenovia, Inc. (EYEN) CEO Michael Rowe on Q3 2022 Results - Earnings Call Transcript
09:52pm, Thursday, 10'th Nov 2022
Eyenovia, Inc. (NASDAQ:EYEN ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Eric Ribner - Investor Relations Michael Rowe - Chief Executive Officer John Gandolfo -
Eyenovia to Report Third Quarter 2022 Results on Thursday, November 10
08:00am, Thursday, 03'rd Nov 2022
Company to host an investor conference call and webcast at 4:30pm ET on that day Company to host an investor conference call and webcast at 4:30pm ET on that day
Eyenovia to Present at the American Academy of Optometry's Annual Meeting
08:00am, Friday, 21'st Oct 2022
NEW YORK, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its
Eyenovia to Present at Upcoming Healthcare Conferences
08:00am, Wednesday, 07'th Sep 2022
NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array
Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q2 2022 Results - Earnings Call Transcript
10:51pm, Wednesday, 10'th Aug 2022
Eyenovia, Inc. (NASDAQ:EYEN ) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Eric Ribner - Investor Relations Sean Ianchulev - Chairman Michael Rowe - Chief Executive
Eyenovia to Report Second Quarter 2022 Results on Wednesday, August 10
08:00am, Thursday, 04'th Aug 2022
Company to host an investor conference call and webcast at 4:30pm ET on that day Company to host an investor conference call and webcast at 4:30pm ET on that day
UPDATE: Eyenovia Announces Virtual 2022 Annual Meeting of Stockholders
10:09am, Thursday, 09'th Jun 2022
NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) investigational produ
Eyenovia Announces Virtual 2022 Annual Meeting of Stockholders
08:00am, Thursday, 09'th Jun 2022
NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) investigational produ
